Thanks for choosing mmm-online.com Sign up for your FREE account now and join the thousands of other healthcare marketing professionals who rely on us for all the latest industry news and innovative ideas for direct and digital strategy. Simply fill out the fields below.

Keep me logged in Forgot your password?

Please wait...

Please wait...

 Obesity

Orexigen, Vivus remain in weight-loss limbo

May 09, 2013

Quarterly reports show that that the weight loss category remains a cool one, but studies indicate that even the best marketing plan will have to overcome payer and pricing issues.
 

Business Briefs Merck, GSK, Novo, Walgreen, Epocrates, Doximity

May 09, 2013

HPV vaccine price cut; Merck files new allergy med with FDA; GSK pursues online transparency; Walgreens ready for greater nurse autonomy; Epocrates ranks high among docs with tablets.
 

Business briefs: Arena, Takeda, Teva, Cubist

May 08, 2013

Arena gets closer to the market place, Takeda scoops up privately held Inviragen, Plan B court decision is coming and Cubist antibotic lands breakthrough therapy status.
 

Analysts on Qsymia: show me the payers

April 17, 2013

Analysts write expanded Qsymia distribution will do little to boost sales if payers are not on board.
 

Hyperbolic OTC obesity drug ads backfire

March 20, 2013

When it comes to OTC weight-loss products, deceptive advertising produces diminishing returns, a study has found.
 

Business briefs: HRT, HPV, Novo Nordisk

March 18, 2013

Researchers find weaknesses in HRT-breast cancer studies, Novo announces GLP-1 weight loss results
 

Vivus launches Qsymia weight-loss app

March 13, 2013

The drug maker is promoting the no-fee, all-access app to healthcare professionals as part of its Qsymia pitch.
 

Company news: Time, Takeda, Amylin, PwC

December 27, 2012

Time Inc. targeted media brand focuses on pharma; Takeda and Amylin call it quits on obesity partnership; PricewaterhouseCoopers builds regulatory intelligence unit
 

Weight-loss category enters 2013 light on results

December 05, 2012

The category that saw its first FDA-approved drug in 13 years is still waiting to take off.
 

Allergan may shed obesity business, GSK a chairman

October 31, 2012

The two companies reported third-quarter earnings along with corporate shake-up news.
 

FDA, EMA take yo-yo approach on diet pills

October 22, 2012

Moves by regulators indicate that the yo-yo effect is not just a patient phenomenon, but one that afflicts drugmakers as well.
 

Study cites surgery's role in preventing type-2 diabetes

August 23, 2012

A study says bariatric surgery can keep patients from becoming diabetic. A bariatric surgeon told MM&M that, while the result isn't a surprise, he doesn't expect the findings to cause the number of surgical patients to spike.
 

Company news: Vivus and Genentech

August 20, 2012

Genentech braced for a Boniva patent cliff, only to come up short, and Vivus' branded obesity drug may face immediate generic competition.
 

Company news: Burson-Marsteller, Corcept and Orexigen

August 07, 2012

PR firm Burson-Marsteller launched a new healthcare subsidiary, Orexigen's net loss widened in Q2, and Corcept closed out its first full quarter with orphan treatment Korlym.
 

Weight loss category gains competitor in Qsymia

July 18, 2012

The FDA approved its second prescription weight loss drug in two months, seeding the new field of contenders to include Vivus' just-greenlighted Qsymia (formerly Qnexa) and Arena's Belviq.
 

Social solutions best high tech in Sanofi contest

July 17, 2012

The candidate to pocket $100,000 for winning its second Data Design Diabetes Innovation Challenge was not one of the entrants that offered tech-centric solutions to diabetes management, but a community-focused proposition that focuses on face-to-face interactions.
 

FDA approves Arena's weight-loss drug

June 27, 2012

Arena Pharmaceuticals' Belviq (lorcaserin) is the first weight-loss drug to be approved in the US in over a decade. Eisai is handling the launch.
 

Company news: Pfizer, Orexigen

May 10, 2012

Reports that Pfizer is pulling out of the Lipitor business are somewhat premature, spokesperson MacKay Jimeson told MM&M.
 

Company news: Vivus

April 10, 2012

Vivus announced Tuesday that the FDA has pushed back the review date for its weight-loss drug Qnexa to July 17.
 

WebMD tackles childhood obesity with new websites

August 17, 2011

WebMD is expanding its wellness and prevention offering with several children's fitness sites aimed at besting childhood obesity.
 

Allergan takes a page from the Tea Party with social campaign

May 17, 2010

Allergan is launching a policy-focused social media campaign promoting its lap-band weight loss surgery with a populist tinge.
 
  

Web Exclusive

Angelina Jolie's fearless but flawed message

Paul Oestreicher, Ph.D. May 17, 2013

Angelina Jolie's story raises important questions about education, outreach and access—but her nod to holistic treatments is less helpful
 

Podcasts

How to engage even the busiest physicians

March 04, 2013

Sponsored by TRUE Health + Wellness. The increasingly demanding schedules of healthcare professionals continue to narrow the window of opportunity for pharma sales teams, and, as a result, marketers are focusing more on non-personal promotion. However, there's a lot more to it than simply bombarding physicians with brand messages, as Anne Stroup, Managing Director at TRUE Health + Wellness, explains to MM&M's James Chase in this special podcast presentation.
 

2013 Hall of Fame Inductees

An entertaining look at the extraordinary lives and careers of the Medical Advertising Hall of Fame's 2013 inductees: Peter Frishauf, Dorothy Philips and David Labson. Clips produced by JUICE Pharma. 

Slideshows

MAHF 2013: Honors Class

A gallery of images from the 2013 Medical Advertising Hall of Fame induction dinner
 
Popular Topics
Acquisition Adherence Advertising App Approval Clinical Trial Consumer COPD Corporate Reputation Diabetes DTC Earnings Elan FDA Generic Generic Drugs iPad Lymphoma Marketing & Communications Merck Mobile Obesity Patients Regulatory Wellness